Article: Bumetanide in heart failure in infancy

The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied. The study was divided into acute (3 days) and long-term (mean 10.5 weeks) cases. A total of 12 male infants was included in the acute study and 13 cases were evaluated in the long-term study. The dose used in the acute study (0.015 mg/kg) was suboptimal; notwithstanding it was found to cause significant natriuresis and chloruresis. Bumetanide in doses varying in different infants from as little as 0.015 mg/kg on alternate days to as much as 0.10 mg/kg daily was shown to be an effective diuretic for long-term use. No side effects were observed in either study.

Citing Articles

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.

Lemonnier E, Villeneuve N, Sonie S, Serret S, Rosier A, Roue M Transl Psychiatry. 2017; 7(3):e1056.

PMID: 28291262 PMC: 5416661. DOI: 10.1038/tp.2017.10.

Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Deidda G, Parrini M, Naskar S, Bozarth I, Contestabile A, Cancedda L Nat Med. 2015; 21(4):318-26.

PMID: 25774849 DOI: 10.1038/nm.3827.

Mineral excretion following furosemide compared with bumetanide therapy in premature infants.

Shankaran S, Liang K, Ilagan N, Fleischmann L Pediatr Nephrol. 1995; 9(2):159-62.

PMID: 7794709 DOI: 10.1007/BF00860731.

Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Ward A, Heel R Drugs. 1984; 28(5):426-64.

PMID: 6391889 DOI: 10.2165/00003495-198428050-00003.

References

1.

Kleeman C, BOHANNAN J, Bernstein D, Ling S, Maxwell M . EFFECT OF VARIATIONS IN SODIUM INTAKE ON CALCIUM EXCRETION IN NORMAL HUMANS. Proc Soc Exp Biol Med. 1964; 115:29-32. View

2.

OLESEN K, Sigurd B, Steiness E, Leth A . Bumetanide, a new potent diuretic. A clinical evaluation in congestive heart failure. Acta Med Scand. 1973; 193(1-2):119-31. View

3.

Bourke E, Asbury M, OSullivan S, Gatenby P . The sites of action of bumetanide in man. Eur J Pharmacol. 1973; 23(3):283-9. DOI: 10.1016/0014-2999(73)90096-4. View

4.

Davies D, Lant A, Millard N, Smith A, Ward J, WILSON G . Renal action, therapeutic use, and pharmacokinetics of the diuretic bumetanide. Clin Pharmacol Ther. 1974; 15(2):141-55. DOI: 10.1002/cpt1974152141. View

5.

Asbury M, Gatenby P, OSullivan S, Bourke E . Bumetanide: potent new "loop" diuretic. Br Med J. 1972; 1(5794):211-3. PMC: 1789187. DOI: 10.1136/bmj.1.5794.211. View

6.

Ostergaard E, Magnussen M, Nielsen C, EILERTSEN E, Frey H . Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic. Arzneimittelforschung. 1972; 22(1):66-72. View

7.

Lim P, Jacob E . Magnesium deficiency in patients on long-term diuretic therapy for heart failure. Br Med J. 1972; 3(5827):620-2. PMC: 1785918. DOI: 10.1136/bmj.3.5827.620. View

8.

FEIT P . Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic acid derivatives. J Med Chem. 1971; 14(5):432-9. DOI: 10.1021/jm00287a014. View

9.

Toft H, Roin J . Effect of frusemide administration on calcium excretion. Br Med J. 1971; 1(5746):437-8. PMC: 1795071. DOI: 10.1136/bmj.1.5746.437. View

10.

Richardson H . Frusemide in heart failure of infancy. Arch Dis Child. 1971; 46(248):520-4. PMC: 1647783. DOI: 10.1136/adc.46.248.520. View

11.

Lees M . Heart failure in the newborn infant. Recognition and management. J Pediatr. 1969; 75(1):139-52. DOI: 10.1016/s0022-3476(69)80116-2. View

12.

Tambyah J, Lim M . Effect of frusemide on calcium excretion. Br Med J. 1969; 1(5646):751-2. PMC: 1982830. DOI: 10.1136/bmj.1.5646.751. View

Bumetanide in Heart Failure in Infancy